Page 69 - CIBEREHD2016-ENG

Study of exosomes before, during and after treatment of HCV infection. • Clinical Research:
Epidemiology of HCV infection.
Development of a National HCV Data Base. HepatiC.
Most relevant scientific articles
• Campos-Varela I., Moreno A., Morbey A., Guaraldi G., Hasson H., Bhamidimarri K.R. et al. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy. Alimentary Pharmacology and Therapeutics. 2016.
• Perales C., Domingo E.. Antiviral strategies based on lethal mutagenesis and error threshold. Current Topics in Microbiology and Immunology. 2016;392:323-339.
• Gregori J., Perales C., Rodriguez-Frias F., Esteban J.I., Quer J., Domingo E.. Viral quasispecies complexity measures. Virology. 2016;493:227-237.
• De Avila A.I., Gallego I., Soria M.E., Gregori J., Quer J., Ignacio Esteban J. et al. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS ONE. 2016;11(10).
• Gallego I, Sheldon J, Moreno E, Gregori J, Quer J, Esteban JI et al. Barrier-Independent, Fitness- Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.Antimicrobial agents and chemotherapy. 2016;60(6):3786-93.
Hightlights
• Our group had led a consortium that has obtained the approval of the CDTI Project IDI20151125 with a total Budget of 8M€ for the next years in collaboration with Roche Sant Cugat: “Plataforma de Medicina de Precisión basada en el desarrollo y uso asistencial de aplicaciones y tecnología de Next-next generation sequencing (NNGS)”.
• Routine clinical use of High-resolution HCV subtyping methodology and exploitation of the EU PATENT No.WO2015001068 A1 will report royalties to CIBER institution in the next weeks.
• We have started studies to patent primers and methods for identification of resistance-associated substitution (RAS) to direct acting antivirals (DAA) used to treat HCV infected patients. CIBER will be well represented. At present, agreements and technical patent documents are being written.
• Our group has centralized the studies of RAS to DAA treatments, based on massive sequencing from the National Strategic Plan for HCV infection 2015. At this moment, 155 RAS reports have been generated for patients from 33 different Hospitals from 9 autonomous communities.
• The methodology of High-resolution HCV subtyping and studies of RAS have been successfully transferred to MiSeq sequencing platform.
• Several studies of accidental Nosocomial HCV transmission have been performed, giving support to the Health Care System.
• A new line of research has been opened; it consists in the study of exosome in serum samples from patients, before, during and after stopping DAA-based treatments.
• Members of the group have actively participated in meetings, congresses and scientific societies.
EHD
research Groups 69